Home

Market Outlook

Today's Market

Summary

Recent White House and FDA actions fast-track psychedelic depression drug approvals, granting priority review vouchers and accelerating rescheduling for eligible therapies.

Compass Pathways leads with a CNPV for COMP360 in treatment-resistant depression, positive Phase 3 data, and a sub-$1bn market cap suggesting potential upside.

AtaiBeckley, Definium Therapeutics, and Cybin (HELP/Helus) also advance with promising data, diverse pipelines, and upcoming pivotal trial catalysts.

The market opportunity is substantial but differentiated by therapy readiness, funding, and near-term catalysts; regulatory and political risks remain material.

Looking for a helping hand in the market? Members of Haggerston BioHealth get exclusive ideas and guidance to navigate any climate.…